Mode
Text Size
Log in / Sign up
Phase 2 Completed N=1,114 Randomized Single-blind Prevention

Comparison of Full-dose Flu Vaccine to Half-dose Flu Vaccine

Source: ClinicalTrials.gov NCT00283283 ↗
Enrolled (actual)
1,114
Serious AEs
0.3%
Results posted
Jun 2020
Primary outcomePrimary: Immune Response: Age 18-49 — 28.8; 21.3; 55.2; 45.0 Anti-body response (GMT)

Summary

This study compared full-dose Flu vaccine to half-dose Flu-vaccine during the 2004-2005 flu season.

Outcome Measures

OutcomeResultp-value
PRIMARY
Immune Response: Age 18-49
28.8; 21.3; 55.2; 45.0; 69.6; 54.8
PRIMARY
Immune Response: Age 50-64
21.4; 14.2; 59.0; 39.1; 52.1; 36.8
SECONDARY
Medical Events: Unsolicited Adverse Events
0; 6; 1; 3; 1193; 2

Eligibility Criteria

Inclusion Criteria

  • Able to understand and comply with all study procedures including availability for all study visits and follow up surveys within 6 months following study enrollment.
  • DEERS eligible beneficiaries eligible for influenza vaccination and able to give informed consent.
  • Age 18-49
  • Patients presenting to travel clinic with no exclusion criteria;
  • Household contacts and out-of-home caretakers of infants from 6-23 months of age;
  • Hospital and/or employees providing service to the public who are not eligible for the post-October 5th recommendations for priority immunization;
  • DOD employees eligible for influenza vaccination prior to October 5th but excluded in the post October 5th guidelines;
  • People living in dormitories or under other crowded conditions, to prevent outbreaks;
  • Ages 50-64 years of age who are not eligible for the post-October 5th recommendations for priority immunization and with no standard of care contraindications to vaccination.
  • Eligible in the Department of Defense for influenza vaccination

Exclusion Criteria

  • all children aged 65 years;
  • persons aged 2-64 years with underlying chronic medical conditions:
  • includes persons with chronic cardiac or pulmonary disease, diabetes mellitus, hemoglobinopathy, or immunosuppressive illness;
  • any acute or chronic condition that, in the opinion of the investigator, would render vaccination unsafe or interfere with the evaluation of response.
  • use of experimental vaccines or medications within 30 days of study entry;
  • receipt of parenteral immunoglobulin within 60 days of study entry;
  • all women who will be pregnant during the influenza season;
  • residents of nursing homes and long-term care facilities;
  • health-care workers involved in direct patient care and included in DOD priority 1; and;
  • military recruits;
  • out-of-home caregivers and household contacts of children aged <6 months.
  • Anyone with clinical contraindications for receiving the inactivated influenza vaccine such as a history of severe allergic reaction to prior influenza vaccinations, severe allergy to egg and/or egg proteins and gelatin.
  • DOD Priority 1: Deployed or deploying (with orders) service members and others designated as critical to national defense.
  • DOD Priority 2: Medically high risk in accordance with ACIP guidelines (includes health-care workers with direct patient contact)
  • Any acute or chronic condition that, in the opinion of the investigator or her provider designee would render vaccination unsafe or interfere with the evaluation of the response.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00283283). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search